After the PTAB invalidated all claims of the '250 Copaxone 40 mg patent, Bernstein analyst Aaron Gal says there is about an 80% chance that generic Copaxone will enter the market in 2017. Gal expects Teva's stock to stabilize at $50-$55. He keeps a $65 price target and Outperform rating on the shares.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."